Evidence Hub

A prospective study on the utilization pattern of vonoprozan on gastroesophageal reflux disease (GERD)

Bhukya Swecha Sanjana Rathod

Indian Journal of Health Care Medical & Pharmacy Practice, 2025

Abstract

Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal condition, which is marked

by retrograde gastric flow to the esophagus resulting in symptoms heartburn and regurgitation. The

increasing prevalence of GERD especially among youngsters has been attributed to beneficial lifestyles, life characteristics as well as malfunction of lower esophageal sphincter. Although proton pump inhibitors (PPIs) are also a frequently used method of therapy, not all patients respond. This was a prospective observational study and lasted six months at PIMS where the efficacy and tolerability of vonoprazan as a novel potassium-competitive acid blocker (P-CAB) were determined in the treatment of erosive and non-erosive GERD.

Two hundred patients took part in this study and the males were the majority (68) and the age group 31- 40 years was the most affected. The use of spicy foods (97.5%), caffeine (78%), and smoking (26.5%) were major contributing lifestyle factors. Vonoprazan 20mg showed high efficacy with regard to reliefof symptoms particularly heartburn, regurgitation, epigastric and nausea with total elimination of severe heartburn in all 112 cases. There was no significant difference between genders and the recovery rates and erosive and non-erosive groups were equal (P=0.31). Some patients had mild residual symptoms reported such as dyspepsia and bloating.

The research finds that vonoprazan is a safe and very effective therapy in GERD with a significant

symptomatic control…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free